CN113509399A - Chitosamine HCl liposome microcapsule, preparation method thereof and application thereof in removing melanin - Google Patents
Chitosamine HCl liposome microcapsule, preparation method thereof and application thereof in removing melanin Download PDFInfo
- Publication number
- CN113509399A CN113509399A CN202110688558.3A CN202110688558A CN113509399A CN 113509399 A CN113509399 A CN 113509399A CN 202110688558 A CN202110688558 A CN 202110688558A CN 113509399 A CN113509399 A CN 113509399A
- Authority
- CN
- China
- Prior art keywords
- chitosamine
- hcl
- phase
- liposome
- stirring
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- QKPLRMLTKYXDST-NSEZLWDYSA-N (3r,4r,5s,6r)-3-amino-6-(hydroxymethyl)oxane-2,4,5-triol;hydrochloride Chemical compound Cl.N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O QKPLRMLTKYXDST-NSEZLWDYSA-N 0.000 title claims abstract description 48
- 239000002502 liposome Substances 0.000 title claims abstract description 42
- 239000003094 microcapsule Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 title abstract description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 15
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229940107161 cholesterol Drugs 0.000 claims abstract description 9
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 9
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims abstract description 8
- 229940083466 soybean lecithin Drugs 0.000 claims abstract description 8
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 7
- 239000002537 cosmetic Substances 0.000 claims abstract description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 7
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 7
- 229940046009 vitamin E Drugs 0.000 claims abstract description 7
- 239000011709 vitamin E Substances 0.000 claims abstract description 7
- 239000007864 aqueous solution Substances 0.000 claims abstract description 3
- 239000000725 suspension Substances 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims description 28
- 238000003756 stirring Methods 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 238000007709 nanocrystallization Methods 0.000 claims description 8
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 6
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 6
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 6
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 4
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 4
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008347 soybean phospholipid Substances 0.000 claims 1
- 210000003491 skin Anatomy 0.000 abstract description 7
- 229940079593 drug Drugs 0.000 abstract description 6
- 239000003814 drug Substances 0.000 abstract description 6
- 210000002752 melanocyte Anatomy 0.000 abstract description 6
- 238000010521 absorption reaction Methods 0.000 abstract description 3
- 230000035699 permeability Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 4
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- OSCJHTSDLYVCQC-UHFFFAOYSA-N 2-ethylhexyl 4-[[4-[4-(tert-butylcarbamoyl)anilino]-6-[4-(2-ethylhexoxycarbonyl)anilino]-1,3,5-triazin-2-yl]amino]benzoate Chemical compound C1=CC(C(=O)OCC(CC)CCCC)=CC=C1NC1=NC(NC=2C=CC(=CC=2)C(=O)NC(C)(C)C)=NC(NC=2C=CC(=CC=2)C(=O)OCC(CC)CCCC)=N1 OSCJHTSDLYVCQC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000004511 skin melanocyte Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/11—Encapsulated compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/55—Phosphorus compounds
- A61K8/553—Phospholipids, e.g. lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/678—Tocopherol, i.e. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Abstract
The invention discloses a chitosamine HCl liposome microcapsule, a preparation method thereof and application thereof in melanin removal. Chitosamine HCl liposome microcapsule, taking chitosamine HCl as effective component, encapsulating the chitosamine HCl in liposome to form suspension; according to weight percentage, the chitosamine HCl is 0.01-0.20%, the liposome is 0.05-1%, and the rest is aqueous solution. The liposome is prepared by dissolving soybean lecithin, cholesterol and vitamin E in anhydrous alcohol. The chitosamine HCl liposome microcapsule prepared by the invention has small nanocrystallized molecular weight, strong permeability and easy absorption; in addition, the skin-care product can decompose melanocytes when being coated on skin, thereby playing a role in removing melanin, and can be applied to cosmetics and medicines.
Description
Technical Field
The invention relates to the technical field of cosmetics, in particular to a chitosamine HCl liposome microcapsule, a preparation method thereof and application thereof in melanin removal.
Background
Chitosamine HCl, english name (INCI): gluconamine HCL, alternative name of ingredients: glucosamine HCL. The existing chitosamine HCl mainly has the effects of resisting static electricity and serving as a hair conditioner in cosmetics and skin care products, has a risk coefficient of 1, is relatively safe, can be safely used, generally has no influence on pregnant women, and has no acne-causing property.
The liposome is a hydrophilic vesicle generally composed of phospholipid bilayers, and has the characteristics of improving the stability of encapsulated drugs, promoting the transdermal absorption of the drugs, prolonging the action time of the drugs, having a targeting effect on local disease parts, reducing the toxic and side effects of the drugs and the like. Thus, liposomes have been widely used as drug carriers in pharmaceutical formulations and cosmetic formulations.
However, due to the structural particularity of chitosamine HCl, liposome preparation is difficult, and the prior art does not describe the chitosamine HCl liposome.
Disclosure of Invention
The invention aims to overcome the defects of the prior art and provides a chitosamine HCl liposome microcapsule, a preparation method thereof and application thereof in melanin removal
In order to achieve the purpose, the invention adopts the following technical scheme:
a chitosamine HCl liposome microcapsule takes chitosamine HCl as an effective component, and the chitosamine HCl is wrapped in liposome to form a suspension; according to weight percentage, the chitosamine HCl is 0.01-0.20%, the liposome is 0.05-1%, and the rest is aqueous solution.
Preferably, in the above chitosamine HCl liposome microcapsule, the liposome is prepared by dissolving soybean lecithin, cholesterol and vitamin E in anhydrous alcohol.
The preparation method of the chitosamine HCl liposome microcapsule comprises the following steps:
(1) dissolving soybean lecithin, cholesterol and vitamin E in anhydrous alcohol, stirring to dissolve completely to obtain liposome as phase I; chitosamine HCl as phase II; dissolving disodium hydrogen phosphate, sodium dihydrogen phosphate, disodium EDTA and HL-10 in sterilized water to obtain phase III;
(2) putting the II-phase chitosamine HCl into a high-pressure micro-jet homogenizer and sterilized water for nanocrystallization;
(3) placing phase I in a round bottle, starting the device at 38-40 deg.C, stirring at 50r/min, and vacuum-0.1 mpa; stirring and evaporating the alcohol until no bubbles emerge from the bottle;
(4) putting part of phase III in a beaker, stirring and dissolving uniformly, adding phase I and phase II, and shaking until phase I and phase II are completely dissolved;
(5) pouring the uniformly mixed liquid obtained in the step (4) into a beaker for homogenizing;
(6) pouring the mixed liquid obtained in the step (5) into a round bottle, starting the device at the temperature of 38-40 ℃, stirring at the temperature of 50r/min, and vacuumizing to 0.1mpa until no bubbles exist in the liquid;
(7) pouring the mixed liquid obtained in the step (6) into a beaker, adding all the residual phase III liquid, magnetically stirring and homogenizing;
(8) pouring the mixed liquid obtained in the step (7) into a high-pressure micro-jet homogenizer again, opening the equipment until no bubbles exist in the liquid, and performing nanocrystallization treatment to obtain the chitosamine HCl liposome microcapsule
Compared with the prior art, the invention has the following beneficial effects: the chitosamine HCl liposome microcapsule prepared by the invention has small nanocrystallized molecular weight, strong permeability and easy absorption; in addition, the skin-care product can be coated on skin to decompose melanocytes, thereby playing a role in removing melanin and whitening skin, and can be applied to cosmetics and medicines.
Drawings
FIG. 1 is an original drawing of skin melanin;
FIG. 2 is an exploded view of melanocytes after 2 days of liposome-encapsulated chitosamine HCl exposure;
FIG. 3 is an exploded view of melanocytes after encapsulation of chitosamine HCl with liposomes for 5 d;
FIG. 4 is an exploded view of melanocytes after 7 days of action of liposome-encapsulated chitosamine HCl.
Detailed Description
Example 1: preparation of chitosamine HCl liposome microcapsules:
(1) dissolving soybean lecithin, cholesterol and vitamin E in anhydrous alcohol, stirring to dissolve completely to obtain liposome as phase I; taking 3g of chitosamine HCl as phase II; dissolving disodium hydrogen phosphate, sodium dihydrogen phosphate, disodium EDTA and HL-10 in sterilized water to obtain phase III;
the formula of the phase I is as follows:
soybean lecithin 15g
Cholesterol 2.85g
200ml of absolute alcohol
Vitamin E1.3 g.
The formula of phase III is:
disodium hydrogen phosphate 14.1g
Sodium dihydrogen phosphate 6.65g
EDTA disodium 2g
Sterilized Water 2000g
HL-10 16g。
(2) Putting the II-phase chitosamine HCl into a high-pressure micro-jet homogenizer and sterilized water for nanocrystallization;
(3) placing phase I in a round bottle, starting the device at 38 deg.C, stirring at 50r/min, and vacuum-0.1 mpa; stirring and evaporating the alcohol until no bubbles emerge from the bottle;
(4) putting part of phase III in a beaker, stirring and dissolving uniformly, adding phase I and phase II, and shaking until phase I and phase II are completely dissolved;
(5) pouring the uniformly mixed liquid obtained in the step (4) into a beaker for homogenizing;
(6) pouring the mixed liquid obtained in the step (5) into a round bottle, starting the equipment, stirring at the temperature of 38 ℃, and carrying out vacuum-0.1 mpa until no bubbles exist in the liquid;
(7) pouring the mixed liquid obtained in the step (6) into a beaker, adding all the residual phase III liquid, magnetically stirring and homogenizing;
(8) and (4) pouring the mixed liquid obtained in the step (7) into a high-pressure micro-jet homogenizer again, starting the equipment until no bubbles exist in the liquid, and carrying out nanocrystallization treatment to obtain the chitosamine HCl liposome microcapsule.
Example 2: preparation of chitosamine HCl liposome microcapsules:
(1) dissolving soybean lecithin, cholesterol and vitamin E in anhydrous alcohol, stirring to dissolve completely to obtain liposome as phase I; taking 3g of chitosamine HCl as phase II; dissolving disodium hydrogen phosphate, sodium dihydrogen phosphate, disodium EDTA and HL-10 in sterilized water to obtain phase III;
the formula of the phase I is as follows:
soybean lecithin 17g
Cholesterol 2.95g
200ml of absolute alcohol
Vitamin E2 g.
The formula of phase III is:
disodium hydrogen phosphate 14.8g
7.65g of sodium dihydrogen phosphate
EDTA disodium 3g
Sterilized Water 2000g
HL-10 14g。
(2) Putting the II-phase chitosamine HCl into a high-pressure micro-jet homogenizer and sterilized water for nanocrystallization;
(3) placing phase I in a round bottle, starting the device at 40 deg.C, stirring at 50r/min, and vacuum-0.1 mpa; stirring and evaporating the alcohol until no bubbles emerge from the bottle;
(4) putting part of phase III in a beaker, stirring and dissolving uniformly, adding phase I and phase II, and shaking until phase I and phase II are completely dissolved;
(5) pouring the uniformly mixed liquid obtained in the step (4) into a beaker for homogenizing;
(6) pouring the mixed liquid obtained in the step (5) into a round bottle, starting the equipment, stirring at 40 ℃, and carrying out vacuum-0.1 mpa until no bubbles exist in the liquid;
(7) pouring the mixed liquid obtained in the step (6) into a beaker, adding all the residual phase III liquid, magnetically stirring and homogenizing;
(8) and (4) pouring the mixed liquid obtained in the step (7) into a high-pressure micro-jet homogenizer again, starting the equipment until no bubbles exist in the liquid, and carrying out nanocrystallization treatment to obtain the chitosamine HCl liposome microcapsule.
Example 3 efficacy test
The chitosamine HCl liposome microcapsule obtained in example 1 is applied to cosmetics and is coated on the surface of the skin, and figure 1 is a skin melanin artwork without the coated chitosamine HCl liposome microcapsule; as can be seen from FIGS. 2-4, the skin melanocytes coated with chitosamine HCl liposome microcapsules have a significant decomposition effect on the melanocytes with the lapse of time.
Claims (4)
1. The chitosamine HCl liposome microcapsule is characterized in that the chitosamine HCl is taken as an active ingredient and is wrapped in liposome to form a suspension; according to weight percentage, the chitosamine HCl is 0.01-0.20%, the liposome is 0.05-1%, and the rest is aqueous solution.
2. The chitosamine HCl liposome microcapsule of claim 1, wherein said liposomes are made from soy lecithin, cholesterol and vitamin E dissolved in anhydrous alcohol.
3. The process for the preparation of chitosamine HCl liposome microcapsule according to claim 1, characterized by comprising the steps of:
(1) dissolving soybean lecithin, cholesterol and vitamin E in anhydrous alcohol, stirring to dissolve completely to obtain liposome as phase I; chitosamine HCl as phase II; dissolving disodium hydrogen phosphate, sodium dihydrogen phosphate, disodium EDTA and HL-10 in sterilized water to obtain phase III;
(2) putting the II-phase chitosamine HCl into a high-pressure micro-jet homogenizer and sterilized water for nanocrystallization;
(3) placing phase I in a round bottle, starting the device at 38-40 deg.C, stirring at 50r/min, and vacuum-0.1 mpa; stirring and evaporating the alcohol until no bubbles emerge from the bottle;
(4) putting part of phase III in a beaker, stirring and dissolving uniformly, adding phase I and phase II, and shaking until phase I and phase II are completely dissolved;
(5) pouring the uniformly mixed liquid obtained in the step (4) into a beaker for homogenizing;
(6) pouring the mixed liquid obtained in the step (5) into a round bottle, starting the device at the temperature of 38-40 ℃, stirring at the temperature of 50r/min, and vacuumizing to 0.1mpa until no bubbles exist in the liquid;
(7) pouring the mixed liquid obtained in the step (6) into a beaker, adding all the residual phase III liquid, magnetically stirring and homogenizing;
(8) and (4) pouring the mixed liquid obtained in the step (7) into a high-pressure micro-jet homogenizer again, starting the equipment until no bubbles exist in the liquid, and carrying out nanocrystallization treatment to obtain the chitosamine HCl liposome microcapsule.
4. The use of chitosamine HCl liposome microcapsules of claim 1 for the preparation of melanin-removing cosmetics.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110688558.3A CN113509399A (en) | 2021-06-22 | 2021-06-22 | Chitosamine HCl liposome microcapsule, preparation method thereof and application thereof in removing melanin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110688558.3A CN113509399A (en) | 2021-06-22 | 2021-06-22 | Chitosamine HCl liposome microcapsule, preparation method thereof and application thereof in removing melanin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113509399A true CN113509399A (en) | 2021-10-19 |
Family
ID=78065758
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110688558.3A Pending CN113509399A (en) | 2021-06-22 | 2021-06-22 | Chitosamine HCl liposome microcapsule, preparation method thereof and application thereof in removing melanin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113509399A (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060018851A1 (en) * | 2004-06-28 | 2006-01-26 | Procyte Corporation | Methods and compositions for preventing and treating hyperpigmentation of skin |
| CN1901920A (en) * | 2003-11-21 | 2007-01-24 | 雀巢技术公司 | Food composition comprising glucosamine |
| CN105581978A (en) * | 2014-10-20 | 2016-05-18 | 湖南师范大学 | Glucosamine derivative cation liposome nanoparticle preparation method |
| CN110652658A (en) * | 2018-06-28 | 2020-01-07 | 强生消费者公司 | Compositions and methods for treating skin disorders using light and glucosamine hydrochloride |
| CN112754949A (en) * | 2021-01-26 | 2021-05-07 | 烟台仙瑟商贸有限公司 | Sustained-release skin-brightening essence composition and preparation method thereof |
-
2021
- 2021-06-22 CN CN202110688558.3A patent/CN113509399A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1901920A (en) * | 2003-11-21 | 2007-01-24 | 雀巢技术公司 | Food composition comprising glucosamine |
| US20060018851A1 (en) * | 2004-06-28 | 2006-01-26 | Procyte Corporation | Methods and compositions for preventing and treating hyperpigmentation of skin |
| CN105581978A (en) * | 2014-10-20 | 2016-05-18 | 湖南师范大学 | Glucosamine derivative cation liposome nanoparticle preparation method |
| CN110652658A (en) * | 2018-06-28 | 2020-01-07 | 强生消费者公司 | Compositions and methods for treating skin disorders using light and glucosamine hydrochloride |
| CN112754949A (en) * | 2021-01-26 | 2021-05-07 | 烟台仙瑟商贸有限公司 | Sustained-release skin-brightening essence composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| 裘炳毅、高志红: "《现代化妆品科学与技术 中》", 31 March 2016, 中国轻工业出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101810160B1 (en) | Generating method for ethosome with bioactive compounds, ethosome and cosmetic composition including ethosome | |
| DE102008034944B4 (en) | microemulsion | |
| Gupta et al. | Transfersomes: the ultra-deformable carrier system for non-invasive delivery of drug | |
| Keller | Liposomes in nutrition | |
| US9849088B2 (en) | Depot formulations of a hydrophobic active ingredient and methods for preparation thereof | |
| US11801302B2 (en) | Formulations and uses thereof | |
| CN103565743B (en) | Tranexamic acid external preparation for skin nanometer formulation and its production and use | |
| CN108904302A (en) | A kind of fullerene topical composition | |
| JP2003533491A (en) | Pharmaceutical and / or cosmetic composition | |
| CN101904814A (en) | Preparation method of drug loaded emulsion | |
| CN109481321B (en) | Flexible tranexamic acid liposome capable of whitening skin and removing freckles as well as preparation method and application thereof | |
| PT1853303E (en) | Stabilized compositions for topical administration and methods of making same | |
| EP2672978A1 (en) | Permeation enhancers for topical formulations | |
| KR20180131876A (en) | Stabilized ceramide complex using liposome technology and manufacturing process thereof and cosmetic composition containing the same | |
| Behtash et al. | New generation of fluconazole: a review on existing researches and technologies | |
| CN101816632B (en) | Composite functional liposome and preparation method and application thereof | |
| CN113509399A (en) | Chitosamine HCl liposome microcapsule, preparation method thereof and application thereof in removing melanin | |
| US20240226060A1 (en) | Topical liposome polyphenol compositions for treating and preventing various skin disorders and methods of preparation thereof | |
| KR101761005B1 (en) | Cosmetic composition containing non-toxic sulfur for sikn moisture, anti-inflammatory and immune enhancement and manufacturing the same | |
| CN102697664B (en) | Tanshinone lipidosome and preparation method thereof | |
| Jain et al. | Ketoconazole laden microemulsion based gel formulation against skin fungal infection | |
| US20070042007A1 (en) | Topical composition for delivery of salicylate esters | |
| CN117651542A (en) | Skin moisturizing composition | |
| CA2877102C (en) | Topical formulations including lipid microcapsule delivery vehicles and their uses | |
| CN113576937A (en) | Preparation method of arbutin solid nano-liposome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20211019 |
|
| RJ01 | Rejection of invention patent application after publication |